Page last updated: 2024-10-30

mazindol and Craniopharyngioma

mazindol has been researched along with Craniopharyngioma in 1 studies

Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

Craniopharyngioma: A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sadatomo, T1
Sakoda, K1
Yamanaka, M1
Kutsuna, M1
Kurisu, K1

Other Studies

1 other study available for mazindol and Craniopharyngioma

ArticleYear
Mazindol administration improved hyperphagia after surgery for craniopharyngioma--case report.
    Neurologia medico-chirurgica, 2001, Volume: 41, Issue:4

    Topics: Appetite Depressants; Craniopharyngioma; Humans; Hyperphagia; Male; Mazindol; Middle Aged; Postopera

2001